OBJECTIVES: Understanding immune response is critical for control of COVID-19 pandemic. However, recent studies show that vaccine-induced humoral immunity may not be long-lasting and weaker in SARS-CoV-2 variants of concern. METHODS: In May 2021, 253 self-nominated persons were tested for antibodies against SARS-CoV-2 in 1 to 104 days (mean 41, median 28) after two doses of Moderna and Pfizer-BioNTech vaccines in the city of Brno, Czechia. Two point-of-care iCHROMATM II immunofluorescence assays were used: COVID-19 Ab against mix of SARS-CoV-2 nucleocapsid and spike proteins (IgG Ab); and COVID-19 nAb against S1-RBD protein (nAb). Results were analysed in relation to gender, age, vaccine, and past COVID-19 disease. RESULTS: Antibodies nAb were detectable in 92.9% (95% CI: 89.7-96.0) of vaccinees. We observed statistically insignificant decrease of positive results from 93.9% (95% CI: 89.5-98.3) and 97.0% (95% CI: 92.8-100.0) in the first and second month after vaccination, respectively, to 91.7% (95% CI: 83.8-99.5) and 78.3% (95% CI: 61.4-95.1) in the third and fourth month, respectively. Quantitative results showed decreasing level of nAb in both genders, age groups and vaccines. Higher levels of nAb were found in younger age group and in COVID-19 convalescents. IgG Ab showed little dynamics in time. CONCLUSIONS: We found robust humoral response after vaccination with mRNA vaccines, however, decreasing nAb levels suggest that vaccine-induced humoral immunity is rapidly waning. This finding is relevant for adjustment of vaccination strategies with regard to inclusion of booster dose(s).

Department of Addictology 1st Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

Spolecnost Podane ruce Brno Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc22020233

003      

CZ-PrNML

005      

20230313104423.0

007      

ta

008      

220802s2022 xr d f 000 0|eng||

009      

AR

024    7_

$a 10.21101/cejph.a7230 $2 doi

035    __

$a (PubMed)35876600

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xr

100    1_

$a Mravčík, Viktor $u Spolecnost Podane ruce, Brno, Czech Republic $u Department of Addictology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic $7 xx0018423

245    10

$a Declining neutralizing antibody levels after SARS-CoV-2 mRNA vaccination: observational data from community point-of-care testing service in Brno, Czechia / $c V. Mravčík, S. Kumpanová Valachovičová, J. Vobořil

520    9_

$a OBJECTIVES: Understanding immune response is critical for control of COVID-19 pandemic. However, recent studies show that vaccine-induced humoral immunity may not be long-lasting and weaker in SARS-CoV-2 variants of concern. METHODS: In May 2021, 253 self-nominated persons were tested for antibodies against SARS-CoV-2 in 1 to 104 days (mean 41, median 28) after two doses of Moderna and Pfizer-BioNTech vaccines in the city of Brno, Czechia. Two point-of-care iCHROMATM II immunofluorescence assays were used: COVID-19 Ab against mix of SARS-CoV-2 nucleocapsid and spike proteins (IgG Ab); and COVID-19 nAb against S1-RBD protein (nAb). Results were analysed in relation to gender, age, vaccine, and past COVID-19 disease. RESULTS: Antibodies nAb were detectable in 92.9% (95% CI: 89.7-96.0) of vaccinees. We observed statistically insignificant decrease of positive results from 93.9% (95% CI: 89.5-98.3) and 97.0% (95% CI: 92.8-100.0) in the first and second month after vaccination, respectively, to 91.7% (95% CI: 83.8-99.5) and 78.3% (95% CI: 61.4-95.1) in the third and fourth month, respectively. Quantitative results showed decreasing level of nAb in both genders, age groups and vaccines. Higher levels of nAb were found in younger age group and in COVID-19 convalescents. IgG Ab showed little dynamics in time. CONCLUSIONS: We found robust humoral response after vaccination with mRNA vaccines, however, decreasing nAb levels suggest that vaccine-induced humoral immunity is rapidly waning. This finding is relevant for adjustment of vaccination strategies with regard to inclusion of booster dose(s).

650    _2

$a neutralizující protilátky $7 D057134

650    _2

$a protilátky virové $7 D000914

650    12

$a COVID-19 $x diagnóza $x prevence a kontrola $7 D000086382

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a lidé $7 D006801

650    _2

$a imunoglobulin G $7 D007074

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a pandemie $7 D058873

650    _2

$a point of care testing $7 D000067716

650    _2

$a messenger RNA $7 D012333

650    _2

$a SARS-CoV-2 $7 D000086402

650    _2

$a vakcinace $7 D014611

650    12

$a virové vakcíny $7 D014765

651    _2

$a Česká republika $x epidemiologie $7 D018153

655    _2

$a časopisecké články $7 D016428

700    1_

$a Kumpanová Valachovičová, Simona, $u Spolecnost Podane ruce, Brno, Czech Republic $d 1987- $7 xx0272944

700    1_

$a Vobořil, Jindřich, $u Spolecnost Podane ruce, Brno, Czech Republic $d 1966- $7 xx0104733

773    0_

$w MED00001083 $t Central European journal of public health $x 1210-7778 $g Roč. 30, č. 2 (2022), s. 111-118

856    41

$u https://pubmed.ncbi.nlm.nih.gov/35876600 $y Pubmed

910    __

$a ABA008 $b B 1829 $c 562 $y p $z 0

990    __

$a 20220802 $b ABA008

991    __

$a 20230313104421 $b ABA008

999    __

$a ok $b bmc $g 1825349 $s 1171479

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2022 $b 30 $c 2 $d 111-118 $e 20220630 $i 1210-7778 $m Central European Journal of Public Health $n Cent. Eur. J. Public Health $x MED00001083

LZP    __

$b NLK198 $a Pubmed-20220802